Gritstone Oncology

$14.18
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$0.72 (+5.35%) Today
$0.00 (0.00%) As of 1:00 AM UTC after-hours

Why Robinhood?

You can buy or sell GRTS and other stocks, options, and ETFs commission-free!

About GRTS

Gritstone Oncology, Inc. clinical-stage biotechnology company, which engages in developing the next generation of cancer immunotherapies to fight multiple cancer types. The company was founded by Andrew Allen, Timothy Chan, Mark Cobbold, Graham Lord, Naiyer Rizvi and Jean-Charles Soria in August 2015 and is headquartered in Emeryville, CA. The listed name for GRTS is Gritstone Oncology, Inc. Common Stock.

CEO
Andrew R. Allen
Employees
174
Headquarters
Emeryville, California
Founded
2015
Market Cap
696.68M
Price-Earnings Ratio
—
Dividend Yield
—
Average Volume
1.07M
High Today
$14.70
Low Today
$13.50
Open Price
$13.50
Volume
607.83K
52 Week High
$35.20
52 Week Low
$2.54

GRTS Earnings

-$0.77
-$0.51
-$0.26
$0.00
Q2 FY19
Q3 FY19
Q4 FY19
Q1 FY20
Q2 FY20
Q3 FY20
Q4 FY20
Estimated
— per share
Actual
Expected Mar 11, Pre-Market

You May Also Like

KFY
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, a registered broker-dealer and Member SIPC. Full disclosure